Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum γ-glutamyltranspeptidase levels

Journal of Gastroenterology

Volumn 31, Issue 1, 1996, Pages 75-80

  Kiso, Shinichi ^a   Kawata, Sumio ^a   Imai, Yasuharu ^a   Tamura, Shinji ^a   Inui, Yoshiaki ^a   Ito, Nobuyuki ^a   Matsuzawa, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

glutamyltranspeptidase; Chronic viral hepatitis C; Interlobular bile duct; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT; BILE DUCT INJURY; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HISTOLOGY; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; CHOLAGOGUES AND CHOLERETICS; CHRONIC DISEASE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C; HUMANS; LINEAR MODELS; LIVER; MALE; MIDDLE AGED; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 0030028668     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01211190     Document Type: Article

References (21)

1. Poupon R, Chretien Y, Poupon RE, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;i:834-836.
2. Chazouilleres O, Poupon R, Capron JP, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990;11:120-123
3. Leuschner U, Leuschner M, Sieratzki J, et al. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985;30:642-649.
4. Chretien Y, Poupon R, Gherardt MF, et al. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut 1989;30: 1110-1115
5. Batta AK, Salen G, Arora R, et al Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis Hepatology 1989;10.414-419.
6. Podda M, Ghezzi C, Battezzati PM, et al. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990;98:1044-1050.
7. Crosignani A, Battezzati PM, Setchell KDR, et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study. Hepatology 1991;13:339-344.
8. Podda M, Ghezzi C, Battezzati PM, et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989;34:59s-65s.
9. Bellentani S, Tabarroni G, Barchi T, et al. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and γ-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled traial. J Hepatol 1989;8:7-12.
10. Buzzelli G, Moscarella S, Focardi G, et al. Long-term treatment with ursodeoxycholic acid in patients with chronic active hepatitis. Curr Ther Res 1991;50:635-642.
11. Ideo G, Bellati G, Pedraglio E, et al. Efficacy of ursodeoxycholic acid in lowering alanine aminotransferase and gamma-glutamyl transpeptidase serum levels in patients with chronic active hepatitis and primary biliary cirrhosis Curr Ther Res 1990;47: 62-66.
12. Poupon RE, Eschwege E, Poupon R, et al. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. J Hepatol 1990;11:16-21.
13. Rolandi E, Franceschini R, Cataldi A, et al. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur J Clin Pharmacol 1991;40:473-476.
14. Takano S, Ito Y, Yokosuka O, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20:558-564.
15. Sherlock S. Hepatitis C viral infection - an update. A supplement to diseases of the liver and biliary system, 8th Ed. Oxford: Blackwell Scientific, 1-9.
16. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis. Hepatology 1992;15:572-577.
17. Cahnus Y, Gane P, Rouger P, et al. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1990;11:12-15.
18. Bateson MC. New directions in primary biiary cirrhosis. BMJ 1990;301:1290-1291.
19. Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial. Gastroenterology 1989;97:1268-1274.
20. Podda M, Ghezzi C, Battezzati PM, et al. Ursodeoxycholic acid for chronic liver diseases. J Clin Gastroenterol 1988;10:S25-S31.
21. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.